Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : 225-Ac PET
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Cyclotron
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ac-225, a core material used for TAT, a new therapeutic concept to attack cancer cells in body, applying a therapeutic agent in which alpha particle-emitting radionuclides that can kill cancer cells are bound to antibodies selectively accumulated in prot...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 04, 2022
Lead Product(s) : 225-Ac PET
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Cyclotron
Deal Size : Inapplicable
Deal Type : Inapplicable